What is William Blair's Forecast for AUTL Q1 Earnings?

Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Autolus Therapeutics in a report issued on Wednesday, April 23rd. William Blair analyst M. Phipps forecasts that the company will post earnings of ($0.27) per share for the quarter. The consensus estimate for Autolus Therapeutics' current full-year earnings is ($0.94) per share. William Blair also issued estimates for Autolus Therapeutics' Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.23) EPS and Q4 2026 earnings at ($0.18) EPS.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.12. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $2.98 million.

Several other equities analysts have also recently weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research note on Thursday, April 10th. Truist Financial decreased their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Finally, Wells Fargo & Company decreased their price target on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday, March 21st. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $9.32.

Autolus Therapeutics Price Performance

Shares of AUTL traded up $0.03 during mid-day trading on Friday, hitting $1.34. 447,786 shares of the company's stock were exchanged, compared to its average volume of 1,451,766. The company has a market cap of $355.24 million, a PE ratio of -1.10 and a beta of 2.06. Autolus Therapeutics has a 52 week low of $1.11 and a 52 week high of $5.00. The company has a 50-day simple moving average of $1.61 and a 200 day simple moving average of $2.42.

Institutional Trading of Autolus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP increased its position in Autolus Therapeutics by 4.6% in the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company's stock valued at $59,562,000 after acquiring an additional 1,125,454 shares during the period. TFG Asset Management GP Ltd increased its position in Autolus Therapeutics by 3.1% in the 4th quarter. TFG Asset Management GP Ltd now owns 8,250,000 shares of the company's stock valued at $19,388,000 after acquiring an additional 250,000 shares during the period. Candriam S.C.A. acquired a new position in Autolus Therapeutics in the 4th quarter valued at approximately $7,500,000. AXA S.A. acquired a new position in Autolus Therapeutics in the 4th quarter valued at approximately $4,288,000. Finally, Millennium Management LLC increased its position in Autolus Therapeutics by 91.6% in the 4th quarter. Millennium Management LLC now owns 1,653,241 shares of the company's stock valued at $3,885,000 after acquiring an additional 790,437 shares during the period. Institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.